All News
EULAR Review of Lifestyle Improvements for Rheumatic Patients
A EULAR taskforce has evaluated the effect of lifestyle behaviors in rheumatic and musculoskeletal diseases (RMDs) and concluded that there is moderate evidence for a small benefit for certain dietary components, but overall, high-level evidence regarding dietary exposures on outcomes in RMDs is lacking.
Read Article
Weight Loss Drugs and the Loss of Skeletal Muscle Mass
d
EurekAlert!
A recent commentary published in The Lancet journal highlights the critical importance of skeletal muscle mass in the context of medically induced weight loss, particularly with the widespread use o
Read Article
A Keto Diet for Autoimmune Disorders?
d
EurekAlert!
Scientists have long suspected the keto diet might be able to calm an overactive immune system and help some people with diseases like multiple sclerosis.
Now, they have reason to believe it could be true.
Read Article
Virtual Yoga Effective in Chronic Low Back Pain
A randomized trial of 140 adults with chronic low back pain (CLBP) demonstrated that virtual yoga instruction resulted in significant improvements in CLBP patients compared to the wait-list control group.
Read Article
ACIP now recommendsa pneumococcal conjugate vaccine (PCV) for all PCV-naive adults >50 yrs. Single dose of PCV (PCV15, PCV20, or PCV21) in adults >50 yrs. Pt 19-64 yrs w/ underlying conditions (prev. recommended) could recv the newly approved PCV21. https://t.co/es4KUuiYqy https://t.co/rVcIgZOLjx
Dr. John Cush RheumNow ( View Tweet)
In an RCT of colchicine vs PBO in #gout for 6 months shows that colchicine prophylaxis when initiating ULT did not increase the odds of achieving gout remission. https://t.co/kgNzw0UUIq https://t.co/ZdBT0Fp9Gx
Dr. John Cush RheumNow ( View Tweet)
Cross-sectional study of 176 CASPAR+ PsA patients correlated Dz activity (cDAPSA) w/ SAA, IL-8, IP10 (IFNg/CXCL10), M-CSF, SCGF-β, SDF-1α) (AUC 0.802- 0.835). The panel was significantly better than CRP (AUC = 0.727, p = 0.022). https://t.co/AZq81S6NH0 https://t.co/5eI241gLVj
Links:
Dr. John Cush RheumNow ( View Tweet)
Metanalysis of 26 RCTs suggests JAK inhibitors have a low, but signif. increased risk of infections (vs placebo) (RR 1.39; 1.096-1.76). No risk of tuberculosis or hepatitis, but an incr. risk of H. zoster was seen (RR 1.71; 0.84-3.51) https://t.co/kXOcldz46l https://t.co/Y5OWk4W1NZ
Links:
Dr. John Cush RheumNow ( View Tweet)
Iberdomide Efficacy in Cutaneous Lupus
berdomide, a cereblon modulator that promotes degradation of transcription factors Ikaros and Aiolos, has been shown in a phase 2 trial to improve outcomes in subacute and chronic cutaneous lupus erythematosus (CLE).… https://t.co/2LtBDOIBrN https://t.co/giVDgZBiyk
Dr. John Cush RheumNow ( View Tweet)
Over a 16 yr span & 988 LBP referrals - 366 (37%) Dx w/ axSpA, w/ increase in # women w/ axSpA. Mean time to Dx decreased 9.8 yrs (2008) to 1 yr (2023). Greatest delay was LBP onset to GP eval. (3.2 yrs). Referral time improved by organizational change https://t.co/bEmaspJWG4 https://t.co/Jyo1neMGib
Dr. John Cush RheumNow ( View Tweet)
Serial MRI study of SI & lumbar (LS) joints in 24 early axSpA (Sxs < 5.5yrs) over 3 yrs, showed:
- SIJ developed bone marrow edema, sclerosis & erosion.
- LS: fat lesions decreased & erosions increased.
- Facet joint inflammation (in t0) significantly influenced yr 3. LS bony… https://t.co/czBPVXYHYa https://t.co/6ByhsXONtf
Dr. John Cush RheumNow ( View Tweet)
FDA's perspective on the use of artificial intelligence in drug development.
- FDA is committed to a risk-based regulatory framework that promotes innovation & protects Pt safety
- Est. CDER AI Council to coordinate, develop, & support internal & external AI-related activities… https://t.co/BLCYmBBJMY https://t.co/fMie3oOfmn
Dr. John Cush RheumNow ( View Tweet)
An 11 yr study of 2187 #RA pts Rx w/ 3068 treatment courses of biologics or JAki, found 275 new cases of #CKD . Compared w/ CTLA4-Ig, TNFi significantly lower CKD rates (HR 0.67), whiile JAKi higher CKD rates (HR 2.16). https://t.co/2Y5BuDzJRs https://t.co/e81lOhOMjX
Dr. John Cush RheumNow ( View Tweet)
Save the date! RheumNows will be covering #ACR24 from 11/14-11/19. Get ready for daily recaps, live streaming and much, much, more! https://t.co/uKc14y1fOm
Dr. John Cush RheumNow ( View Tweet)
Myelitis Associated With Rheumatologic Dz studied in 41 pts (age 44yrs; 95%women). Dx: SLE (41%), Sjogrens (24%), UCTD (15%), Overlap (12%) w/ APL syndr. Half Dx were AQP4-IgG Ab+ (90% w/ extensive cord lesions), 7% MOGAD Ab+, 44% "double-seronegative" myelitis.… https://t.co/or6vuCZASs https://t.co/UxzSR6yJO5
Dr. John Cush RheumNow ( View Tweet)
Overview of IL-23 inhibition for chronic inflammatory disease (partial read) from Lancet. Started with targeting the p40 subunit shared between IL-12 & IL-23A. Now we have specific inhibitors of the p19 protein of IL-23A. These agents are superior to TNFi in plaque… https://t.co/ud61WLgWs2 https://t.co/fQ7WhLyrsi
Dr. John Cush RheumNow ( View Tweet)
Hydroxychloroquine effects studied in 30pts (23 RA, 7SLE). Results did not support that HCQ may reduce CV risk - Arterial stiffness was not affected by HCQ, HCQ modestly lowered HbA1c & lipids - yet HCQ has been shown to reduced CV risk in observational studies… https://t.co/n283HwvRm4 https://t.co/lQN342uevy
Dr. John Cush RheumNow ( View Tweet)
SGLT2 Inhibitor Protective Effects in Lupus
Systemic lupus erythematosus (SLE) outcomes were assessed based on whether they received sodium-glucose co-transporter 2 inhibitors (SGLT2i), in the setting of comorbid type 2 diabetes (T2D).
https://t.co/I5ZrA9pXRU https://t.co/8U0ILPbMuN
Dr. John Cush RheumNow ( View Tweet)
Swapping is Better than Cycling in Psoriatic Arthritis
A real-world cohort study suggests that psoriatic arthritis failing to respond to TNF inhibitors (TNFi) may do better if they subsequently swap to an IL-17 inhibitor (IL-17i), rather than cycling to another TNFi.… https://t.co/VREQCx8TfI https://t.co/ylzYPHhedi
Dr. John Cush RheumNow ( View Tweet)
Study of 168 patients with MDA5-positive Dermatomyositis finds that elevated IL-6 (≥ 13.41pg/m), lymphopenia (< 0.5 × 109) older age and high LDH predicted 6-month all-cause mortality in DM https://t.co/eHYrUtvsI9 https://t.co/SAy27Om2zu
Dr. John Cush RheumNow ( View Tweet)